» Articles » PMID: 35847898

Mouse Models of Hepatocellular Carcinoma: Classification, Advancement, and Application

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Jul 18
PMID 35847898
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the subtype of liver cancer with the highest incidence, which is a heterogeneous malignancy with increasing incidence rate and high mortality. For ethical reasons, it is essential to validate medical clinical trials for HCC in animal models before further consideration on humans. Therefore, appropriate models for the study of the pathogenesis of the disease and related treatment methods are necessary. For tumor research, mouse models are the most commonly used and effective model, which is closer to the real-life environment, and the repeated experiments performed on it are closer to the real situation. Several mouse models of HCC have been developed with different mouse strains, cell lines, tumor sites, and tumor formation methods. In this review, we mainly introduce some mouse HCC models, including induced model, gene-edited model, HCC transplantation model, and other mouse HCC models, and discuss how to choose the appropriate model according to the purpose of the experiments.

Citing Articles

Liver sinusoidal endothelial cells regulate the balance between hepatic immunosuppression and immunosurveillance.

Kremer K, Khammash H, Miranda A, Rutt L, Twardy S, Anton P Front Immunol. 2025; 15:1497788.

PMID: 39896805 PMC: 11782242. DOI: 10.3389/fimmu.2024.1497788.


Liver Cancer Neuroscience: Regulating Liver Tumors via Selective Hepatic Vagotomy.

Bauer K, Ghabra S, Ma C, Chedester L, Greten T Methods Protoc. 2024; 7(6).

PMID: 39728619 PMC: 11677442. DOI: 10.3390/mps7060099.


infection downregulates hypoxia‑inducible factor 1α expression to suppress the vascularization and tumorigenesis of liver cancer.

Wu R, Chen X, Chen H, Li M, Liang Y Oncol Lett. 2024; 28(6):604.

PMID: 39483968 PMC: 11525613. DOI: 10.3892/ol.2024.14737.


Resistance against the development of diethylnitrosamine-induced hepatocellular carcinoma in female C3H mice: an experimental model.

Montagna D, Todero M, Postma G, Trigo R, Bernal A, Bustuoabad O Exp Anim. 2024; 73(4):399-411.

PMID: 39098024 PMC: 11534494. DOI: 10.1538/expanim.23-0149.


Mechanistically based blood proteomic markers in the TGF-β pathway stratify risk of hepatocellular cancer in patients with cirrhosis.

Xiang X, Bhowmick K, Shetty K, Ohshiro K, Yang X, Wong L Genes Cancer. 2024; 15():1-14.

PMID: 38323119 PMC: 10843195. DOI: 10.18632/genesandcancer.234.


References
1.
Zhang S, Song X, Cao D, Xu Z, Fan B, Che L . Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. J Hepatol. 2017; 67(6):1194-1203. PMC: 5696057. DOI: 10.1016/j.jhep.2017.07.006. View

2.
Hsu S, Wang B, Kota J, Yu J, Costinean S, Kutay H . Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest. 2012; 122(8):2871-83. PMC: 3408748. DOI: 10.1172/JCI63539. View

3.
Murakami H, SANDERSON N, Nagy P, Marino P, Merlino G, Thorgeirsson S . Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. Cancer Res. 1993; 53(8):1719-23. View

4.
Huch M, Knoblich J, Lutolf M, Martinez-Arias A . The hope and the hype of organoid research. Development. 2017; 144(6):938-941. DOI: 10.1242/dev.150201. View

5.
Infante J, Tschanz C, Shaw N, Michaud A, Lawrence P, Brenna J . Straight-chain acyl-CoA oxidase knockout mouse accumulates extremely long chain fatty acids from alpha-linolenic acid: evidence for runaway carousel-type enzyme kinetics in peroxisomal beta-oxidation diseases. Mol Genet Metab. 2002; 75(2):108-19. DOI: 10.1006/mgme.2001.3279. View